Status In progress
Process STA
ID number 993

Provisional Schedule

Expected publication 25 July 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Psoriasis and Psoriatic Arthritis Alliance
  Psoriasis Association
Professional groups British Association of Dermatologists

Commentators

Comparator companies Abbvie - CAU not returned, not participating
  Aspire Pharma - CAU not returned, not participating
  Biogen Idec Ltd
  Celgene - CAU not returned, not participating
  Hameln pharmaceuticals - CAU not returned, not participating
  Hospira UK -CAU not returned, not participating
  Janssen
  Medac UK - CAU not returned, not participating
  Merck Sharp & Dohme
  Napp - CAU not returned, not participating
  Nordic Pharma - CAU not returned, not participating
  Novartis
  Orion Pharma - CAU not returned, not participating
  Pfizer
  Rosemont pharmaceuticals - CAU not returned, not participating
  Sandoz - CAU not returned, not participating
  Sanofi - CAU not returned, not participating
  Teva UK - CAU not returned, not participating
  UCB Pharma - CAU not returned, not participating
  Zentiva UK - CAU not returned, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
25 September 2017 Invitation to participate
20 March 2017 Referral
20 March 2017 In progress, Topic referred
26 September 2016 - 24 October 2016 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance